As a first step, we determined the preexisting activation (CD62P expression) of platelets ex vivo in our cohort, which revealed 19.4% CD62P-positive platelets (95%CI: 10.4–38.6) in HD and 18.6% (95%CI: 6.3–49.8) in breast cancer patients and thus similar platelet activation levels (p = 0.57, Fig. 2a). This evidence concerns the gene SELP and breast cancer.